Articles related to TYPE 2 DIABETES
GLP-1 Receptor Agonists Associated with Thyroid Cancer
Looking at 2,500 case patients mapped to more than 45,000 controls, the hazard ratio for all thyroid cancers in GLP-1 users was 1.46. The hazard ratio for developing thyroid cancer with DPP-4 inhibitors was 1.1. GLP-1 receptors are present in normal and cancerous thyroid cells.
Endocrinology, Diabetes, Metabolism November 28th 2022
Intermittent Fasting: What is It, and How Does It Work?
The extra calories and lower physical activity of modern culture are yielding higher rates of obesity, type 2 diabetes, heart disease, and other illnesses. Evidence is mounting that intermittent fasting may help reverse these trends. This neuroscientist brings 25 of studying intermittent fasting to explain why and how it works, and what your patients’ options are.
Cardiology November 14th 2022
A Deeper Look at Hollywood’s Newest Weight Loss Drug
Shortages of GLP-1 agonists are being driven by the number of Americans being overweight and the hype from Hollywood on the drug. But these aren’t the best choice for everyone seeking to lose weight.
Endocrinology, Diabetes, Metabolism November 9th 2022
Is NAD Therapy All It’s Cracked Up to Be? Here’s the Evidence
The evidence for NAD supplement effectiveness at present comes only from animal models and very small-scale human studies. And some studies link excessive consumption of NADH to anxiety and insomnia, and NAD precursors to Parkinson’s disease and diabetes.
All Specialties October 26th 2022
NIH Study Compares Four Commonly Used Type 2 Diabetes Medications
In the 5-year, multi-center, randomized, controlled GRADE trial (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study), insulin glargine and liraglutide were about 13% more effective than glimepiride in keeping HbA1c lower than 7.0%, and 30% more effective than sitagliptin.
Endocrinology, Diabetes, Metabolism October 3rd 2022
Diabetes Medication May be Effective for Weight Loss
Because this GLP-1 agonist is known to reduce food intake, physicians have been prescribing tirzepatide off-label for weight loss for years. But unlike other drugs in its class, tirzepatide targets GLP-1 and GIP receptors.
Endocrinology, Diabetes, Metabolism September 26th 2022